Loading
companiesCompany
Nerviano Medical Sciences
Nerviano Medical Sciences is an Italian drug-discovery company founded in 2004 in Nerviano, near Milan, that leads two cancer trials in OnCo: the PARP1-selective inhibitor atamparib in advanced solid tumours and NMS-03305293 with temozolomide in recurrent glioblastoma.
Also called: Nerviano Medical Sciences Ltd.Nerviano Medical Sciences (Shanghai) Ltd.Nerviano Medical Sciences S.r.l.NMS
Overview
Nerviano Medical Sciences is a company based in Nerviano, Italy, founded in 2004 (Wikidata Q30280722, which also gives its website). ClinicalTrials.gov classes it as an industry sponsor; its Shanghai subsidiary is the registered sponsor of one trial. It leads two phase 1/2 trials recorded in OnCo: NCT07374419 (atamparib in advanced solid tumours, recorded under NSCLC) and NCT04910022 (NMS-03305293 with temozolomide in adults with recurrent glioblastoma). Both compounds are its own, the basis for the biotech type.
Headquarters
Nerviano, IT
Scorecard
All companies#137of 1244 companies, score 42
- approved products +6
- modalities +2
- regions +4
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 0 targets, 839 registry studies. Formula on the scorecards page.
Type
Website
Founded
2004
ApprovedOral alkylating chemotherapy
Temozolomide · Temodar
The only chemotherapy proven to extend life in glioblastoma, given during and after radiation. It works best when the tumour has switched off a repair gene called MGMT.
Similar pages
- CompanyImmunovaccine (IMV)
Shares Non-small-cell lung cancer and the tag wave5-sponsor.
- TrialA Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
Shares Temozolomide, Glioma & glioblastoma.
- TrialA Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Shares Temozolomide, Glioma & glioblastoma.
- TrialA Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Shares Temozolomide, Glioma & glioblastoma.
- TrialA Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Shares Temozolomide, Glioma & glioblastoma.
- TrialStudy of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
Shares Temozolomide, Glioma & glioblastoma.
- TrialJK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
Shares Temozolomide, Glioma & glioblastoma.
- TrialIntraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
Shares Temozolomide, Glioma & glioblastoma.